Accounting for Cured Patients in Cost-Effectiveness Analysis - Othus, Megan; Bansal, Aasthaa; Koepl, Lisel; Wagner, Samuel; Ramsey, Scott (Value in health, 2017)
Keywords: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - economics; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - economics; Antineoplastic Agents - therapeutic use; Bias; Cancer; Clinical research; Clinical trials; Confidence intervals; Cost analysis; Cost-Benefit Analysis; Cure; cure models; Data processing; Drug Costs; Economics; Female; Glycoprotein gp100; Glycoproteins - adverse effects; Glycoproteins - economics; Glycoproteins - therapeutic use; Health economics; Heterogeneity; Humans; Internal Medicine; Ipilimumab; Kaplan-Meier Estimate; Male; Medical treatment; Melanoma; Melanoma - drug therapy; Melanoma - economics; Melanoma - mortality; Middle Aged; Models, Economic; Monoclonal antibodies; Mortality; Oncology; overall survival; Quality adjusted life years; Randomized Controlled Trials as Topic; Remission Induction; Skin melanoma; Skin Neoplasms - drug therapy; Skin Neoplasms - economics; Skin Neoplasms - mortality; Statistical analysis; Statistical methods; Survival analysis; Survivor; Survivors; Time Factors; Treatment Outcome; Young Adult; overall survival; cure models; survival analysis; oncology